Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $1 | $0 | $0 |
| Gross Profit | -$1 | -$0 | -$0 |
| % Margin | – | – | – |
| R&D Expenses | $61 | $28 | $9 |
| G&A Expenses | $22 | $8 | $1 |
| SG&A Expenses | $22 | $8 | $1 |
| Sales & Mktg Exp. | $0 | -$0 | $0 |
| Other Operating Expenses | -$1 | $0 | -$0 |
| Operating Expenses | $82 | $36 | $10 |
| Operating Income | -$83 | -$36 | -$10 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $5 | $1 | -$0 |
| Pre-Tax Income | -$78 | -$35 | -$11 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$78 | -$35 | -$11 |
| % Margin | – | – | – |
| EPS | -0.38 | -0.19 | -0.053 |
| % Growth | -100% | -258.5% | – |
| EPS Diluted | -0.38 | -0.19 | -0.053 |
| Weighted Avg Shares Out | 207 | 181 | 201 |
| Weighted Avg Shares Out Dil | 207 | 181 | 201 |
| Supplemental Information | – | – | – |
| Interest Income | $12 | $3 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 |
| EBITDA | -$77 | -$35 | -$10 |
| % Margin | – | – | – |